Dompé

Executive Summary

Dompé is a privately held, family-owned Italian biopharmaceutical company with over 130 years of history, headquartered in Milan. The company specializes in first-in-class, disease-modifying therapies, leveraging its proprietary recombinant human Nerve Growth Factor (rhNGF) platform for ophthalmic, neurological, and pain indications. Dompé also operates Exscalate, a supercomputing-powered drug discovery engine that accelerates target identification and lead optimization. While the company has a legacy of commercial products, its current focus is on advancing a pipeline of novel biologics and small molecules into clinical development, with rhNGF being the most advanced asset. Dompé's unique position lies in its dual approach: combining a well-understood biological pathway (NGF) with computational drug discovery. The rhNGF program has shown promise in corneal neurotrophic keratitis and other ocular surface disorders, with potential for expansion into neurodegenerative diseases. Dompé's strategy involves strategic partnerships and out-licensing to maximize asset value. Given its robust cash position from existing revenues and family ownership, the company is less reliant on external capital, allowing it to pursue long-term value creation. However, as a private entity, transparency is limited, and key upcoming milestones will be critical to assess progress and valuation.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for rhNGF in neurotrophic keratitis70% success
• H1 2026New partnership for Exscalate platform with major pharma50% success
• Q4 2026Regulatory filing for rhNGF in Europe (EMA submission)60% success